Introduction {#sec1-0300060518815364}
============

Invasive ductal carcinoma (IDC), the most common type of breast cancer, accounts for 80% of breast cancer cases.^[@bibr1-0300060518815364]^ Around 45% to 78% of invasive breast cancers are associated with ductal carcinoma *in situ* (DCIS), which is a subtype of breast cancer that proliferates within mammary ducts and lobules without stromal invasion.^[@bibr2-0300060518815364],[@bibr3-0300060518815364]^ However, the importance of DCIS in malignant progression remains unclear. It was previously thought that DCIS was an early step from normal breast tissue to invasive breast cancer,^[@bibr4-0300060518815364]^ but recent studies reported similarities between DCIS and invasive cancer at the genomic level.^[@bibr5-0300060518815364][@bibr6-0300060518815364]--[@bibr7-0300060518815364]^ Proliferation and apoptosis-related proteins, including estrogen receptor (ER) and progesterone receptor (PR), share similar expression patterns in the *in situ* and invasive components of DCIS and IDC samples, suggesting that they may play a role in the transition process.^[@bibr8-0300060518815364],[@bibr9-0300060518815364]^ Additionally, the same tumor suppressor genes located on chromosome 11 can be mutated or deficient in these two breast cancers.^[@bibr10-0300060518815364],[@bibr11-0300060518815364]^

A long-term follow up study^[@bibr12-0300060518815364],[@bibr13-0300060518815364]^ reported likely changes at the molecular level in the progression from DCIS to IDC given that 50% of high-grade DCIS progressed to IDC over 3 years. These changes are not only thought to involve proliferation and apoptosis-related proteins, but also invasion and progression-related genes and tumor suppressor genes. The matrix metalloproteinase 11 gene (*MMP11*), which is associated with breast cancer invasion, is a key factor for tumor development, and is highly expressed in IDC compared with matched DCIS.^[@bibr14-0300060518815364]^ Importantly, high levels of *MMP11* expression are associated with the invasion of multiple human carcinomas (including breast cancer) and poor clinical outcome for patients.^[@bibr15-0300060518815364]^ *MMP11* plays a role in the paracrine anti-apoptotic function, which benefits cancer survival.^[@bibr16-0300060518815364]^ Therefore, investigating the molecular changes that occur in DCIS and in its transition to IDC may benefit our understanding of breast tumor invasion and progression by identifying possible target genes and biological processes and pathways.

Schuetz et al. previously identified several progression-specific candidate genes such as *GREM1*, *SART2*, and *LRRC15* by analyzing the gene expression profiling of tumor samples between matched DCIS and IDC samples, combined with laser capture microdissection and oligonucleotide microarray analysis.^[@bibr14-0300060518815364]^ Additionally, Kim et al. identified associated genomic alterations from DCIS to IDC by performing whole-exome sequencing and copy number profiling.^[@bibr17-0300060518815364]^ They found several well-known mutations including those in *TP53*, *PIK3CA*, and *AKT1*, and copy number alterations (CNAs) in pure DCIS; however, significantly fewer driver genes and co-occurrences of mutations and CNAs were detected than in synchronous DCIS-IDC. The present study aimed to investigate gene alterations leading to the progression from DCIS to IDC by analyzing the gene profiles of DCIS and IDC from Gene Expression Omnibus (GEO) datasets GSE21422 and GSE3893.

Materials and methods {#sec2-0300060518815364}
=====================

Gene expression data collection and processing {#sec3-0300060518815364}
----------------------------------------------

The gene expression profile of GSE21422, including nine DCIS and five IDC samples, was obtained from the GEO (<http://www.ncbi.nlm.nih.gov/geo/>) dataset. Samples were tumor grade 2 and 3 (six DCIS and three IDC at grade 3, and three DCIS and two IDC at grade 2); all patients were free of distant metastasis.^[@bibr18-0300060518815364]^ The GPL570 Affymetrix Human Genome U133 Plus 2.0 Array platform was used in this dataset. Gene expression data based on the GPL570 platform in GSE3893 was also downloaded from the GEO dataset. This dataset contains seven breast tumors, which were diagnosed to contain both DCIS and IDC, of histological grades 2 and 3.^[@bibr14-0300060518815364]^ Seven DCIS samples and seven IDC samples were isolated from the seven tumors with significant DCIS and IDC components. Two of the seven tumors were stratified into a homogenous ER-negative tumor cluster, and the others were ER-positive. Four of the seven tumors were PR-negative, and the others were PR-positive. Four of the seven tumors were human epidermal growth factor receptor (HER)2-negative, and the others were HER2-positive.

Gene expression data from each sample were extracted and downloaded from Series Matrix File(s). Probes were mapped to genes using Perl,^[@bibr19-0300060518815364]^ and R was performed to pre-process the data via background correction and quantile normalization. Then, an "impute" package^[@bibr20-0300060518815364]^ was applied to complement the missing expression by using its adjacent value. Finally, a data file containing available Entrez Gene identifiers and their corresponding expression values was obtained. The need for approval by an ethics review committee was waived because all gene expression data were downloaded from the GEO dataset.

Identification of differentially expressed genes (DEGs) {#sec4-0300060518815364}
-------------------------------------------------------

R was also adopted to screen DEGs. Log2 (fold changes) in gene expression were calculated and used in the analysis. The Limma package was employed to identify DEGs in each comparison using the empirical Bayes method.^[@bibr21-0300060518815364]^ To correct for multiple testing, *P* values were adjusted using the 'fdr' function, which uses the Benjamini--Hochberg method to control the false discovery rate. The threshold to screen out DEGs was \|log2(fold change)\| \> 0.3 and *P* \< 0.05. Subsequently, we identified the common genes altered in both datasets with consistent up-or down-regulation for further analysis.

Pathway enrichment analysis {#sec5-0300060518815364}
---------------------------

The common DEGs consistently altered in both datasets were annotated for protein function. R package-GO.db,^[@bibr22-0300060518815364]^ KEGG.db,^[@bibr23-0300060518815364]^ and KEGGREST^[@bibr24-0300060518815364]^ were used to analyze functional enrichment. The statistical significance of the gene ontology (GO) term was evaluated with a threshold of *P* \< 0.05. Common DEGs were further classified into different biological pathways. Similar to GO terms, the threshold for significant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was also set as *P* \< 0.05.

Oncomine database analysis {#sec6-0300060518815364}
--------------------------

Oncomine is a cancer microarray database and web-based data mining platform that aims to facilitate discovery from genome-wide expression analyses.^[@bibr25-0300060518815364]^ The Oncomine microarray database (<http://www.oncomine.org>) was used to detect gene expression levels of major histocompatibility complex, class II, DR alpha (*HLA-DRA*), complement C3a receptor 1 (*C3AR1*), and FYN binding protein (*FYB*) in different types of breast tumor samples. First, we compared clinical samples of cancer with healthy control datasets, and used a Students' *t*-test to generate *P* values. We also focused on clinical specimens of high grade *vs.* low grade, recurrence at 3 years *vs.* no recurrence at 3 years, and metastasis at 3 years *vs*. no metastasis at 3 years. Associations between these genes in different types of breast cancer and different studies were also observed.

Results {#sec7-0300060518815364}
=======

Screening DEGs between DCIS and IDC in each GEO dataset and cluster analysis {#sec8-0300060518815364}
----------------------------------------------------------------------------

Gene expression data for each sample were downloaded from GSE21422 and GSE3893. GSE21422 included nine DCIS samples and five IDC samples, and GSE3893 consisted of seven DCIS samples and seven IDC samples. Hierarchical clustering and volcano plots revealed 1078 DEGs (\|log2(fold change)\| \> 0.3 and *P* \< 0.05) in IDC compared with DCIS from GSE21422 as shown in [Figure 1](#fig1-0300060518815364){ref-type="fig"}, including 585 up-regulations. A total of 862 DEGs were identified in IDC from GSE3893 with 720 upregulated genes ([Figure 2](#fig2-0300060518815364){ref-type="fig"}, *P* \< 0.05).

![Identification of DEGs from the GSE21422 dataset. (a) Hierarchical clustering heat map of DCIS and IDC. Horizontal axis indicates the DEGs, vertical axis indicates the sample. Green represents downregulated genes, red represents upregulated genes. (b) Volcano plot of DCIS and IDC. Green represents downregulated DEGs, red represents upregulated DEGs.](10.1177_0300060518815364-fig1){#fig1-0300060518815364}

![Identification of DEGs from the GSE3893 dataset. (a) Hierarchical clustering heat map of DCIS and IDC. Horizontal axis indicates the DEGs, vertical axis indicates the sample. Green represents downregulated genes, red represents upregulated genes. (b) Volcano plot of DCIS and IDC. Green represents downregulated DEGs, red represents upregulated DEGs.](10.1177_0300060518815364-fig2){#fig2-0300060518815364}

Identification of conserved genes and pathway enrichment analysis {#sec9-0300060518815364}
-----------------------------------------------------------------

To identify conserved genes, we overlapped the DEGs in the two datasets. A total of 26 genes were common to both datasets ([Table 1](#table1-0300060518815364){ref-type="table"}, *P* \< 0.05). Among these, *MMP11*, *KRT14*, *KRT17*, and *RGS1* were all upregulated in our analysis, and have been reported to be correlated with breast tumor invasion or poor prognosis.

###### 

Twenty-six common differentially expressed genes with consistent up- and down-regulation in both Gene Expression Omnibus datasets.

![](10.1177_0300060518815364-table1)

  Gene        GSE21422   GSE3893            
  ----------- ---------- --------- -------- --------
  *TAGAP*     0.37       0.0265    0.46     0.0059
  *PIK3AP1*   0.47       0.0124    0.42     0.0006
  *ST8SIA4*   0.32       0.0389    0.65     0.0003
  *GPRIN3*    0.58       0.0384    0.39     0.0026
  *LAIR1*     0.73       0.0020    0.33     0.0007
  *NGFR*      --0.56     0.0276    --0.50   0.0038
  *PLXNC1*    0.70       0.0109    0.42     0.0020
  *TAP2*      0.79       0.0371    0.38     0.0150
  *FCGR2A*    0.75       0.0288    0.42     0.0002
  *MYH11*     --1.64     0.0022    --0.31   0.0056
  *MMP11*     1.38       0.0370    0.39     0.0002
  *SAMSN1*    0.95       0.0449    0.59     0.0025
  *C3AR1*     0.77       0.0452    0.74     0.0001
  *FYB*       1.42       0.0099    0.40     0.0015
  *TFEC*      1.58       0.0415    0.50     0.0154
  *ADORA3*    1.51       0.0139    0.65     0.0001
  *RGS1*      1.52       0.0298    0.76     0.0133
  *DSC3*      --1.17     0.0006    --1.18   0.0065
  *DST*       --3.24     0.0069    --0.46   0.0012
  *HLA-DRA*   1.11       0.0063    1.45     0.0018
  *EPYC*      2.71       0.0485    0.85     0.0333
  *FCGR3B*    3.21       0.0001    0.80     0.0015
  *ACTG2*     --4.06     0.0000    --1.06   0.0001
  *ANXA8L1*   --3.74     0.0001    --1.19   0.0080
  *KRT17*     --3.57     0.0001    --1.93   0.0071
  *KRT14*     --5.84     0.0012    --3.10   0.0002

These 26 conserved genes were next used to perform pathway analysis, which identified 78 GO processes and eight KEGG pathways. The conserved genes were mainly enriched in intermediate filament-based processes, the immune response, the Staphylococcus aureus infection response, and phagosomes. In the top 20 significant GO processes and all KEGG pathways, *FCGR2A* was associated with 10 GO processes and five KEGG pathways; *HLA-DRA* was involved in six GO processes and five KEGG pathways; and *C3AR1* and *FYB* were associated with 10 GO terms. Importantly, these genes were all involved with the immune response. These findings suggest that *FCGR2A*, *HLA-DRA*, *C3AR1*, and *FYB* might play crucial roles in the progression of DCIS to IDC, so were worthy of further investigation.

Validation for the expression of HLA-DRA, C3AR1 and FYB by Oncomine analysis {#sec10-0300060518815364}
----------------------------------------------------------------------------

Oncomine gene expression array datasets ([www.oncomine.org](http://www.oncomine.org)), an online cancer microarray database, facilitate discovery from genome-wide expression analyses.^[@bibr25-0300060518815364]^ No study has reported the association of breast cancer with *HLA-DRA*, *C3AR1*, or *FYB*; therefore, we extracted their expression data from the Oncomine database for breast carcinoma, focusing on the clinical samples of patients with cancer *vs.* healthy controls, high grade *vs.* low grade, recurrence at 3 years *vs.* no recurrence at 3 years, and metastasis at 3 years *vs*. no metastasis at 3 years.

Different Oncomine datasets revealed that *HLA-DRA* was significantly overexpressed in IDC and ductal breast carcinoma ([Table 2](#table2-0300060518815364){ref-type="table"}, *P* \< 0.05; [Figure 3a and 3b](#fig3-0300060518815364){ref-type="fig"}, *P* \< 0.05). High expression of *HLA-DRA* was also observed in N1+ stage breast carcinoma compared with N0 stage ([Figure 3c](#fig3-0300060518815364){ref-type="fig"}, *P* \< 0.01). Importantly, elevated *HLA-DRA* levels were also associated with breast carcinoma recurrence after 5 years ([Figure 3d](#fig3-0300060518815364){ref-type="fig"}, *P* \< 0.05). Similar to *HLA-DRA*, *C3AR1* was also increased in different types of breast carcinoma in different datasets, and its overexpression was also observed in N1+ stage breast carcinoma ([Table 2](#table2-0300060518815364){ref-type="table"}, [Figure 4](#fig4-0300060518815364){ref-type="fig"}, *P* \< 0.05). Moreover, *FYB* up-regulation was also correlated with high grade IDC, breast carcinoma recurrence, and metastasis ([Table 2](#table2-0300060518815364){ref-type="table"}, [Figure 5](#fig5-0300060518815364){ref-type="fig"}, *P* \< 0.05).

![*HLA-DRA* expression validation in different types of breast cancer from different Oncomine databases. (a) and (b) High expression of *HLA-DRA* is observed in breast cancer compared with healthy breast samples. (c) *HLA-DRA* is overexpressed in N1+ stage breast carcinoma compared with N0 stage. (d) *HLA-DRA* is upregulated in breast carcinoma with recurrence at 5 years.](10.1177_0300060518815364-fig3){#fig3-0300060518815364}

![*C3AR1* expression validation in different types of breast cancer from different Oncomine databases. (a) and (b) *C3AR1* expression is increased in breast cancer. (c) Elevated expression of *C3AR1* is found in N1+ stage breast carcinoma compared with N0 stage.](10.1177_0300060518815364-fig4){#fig4-0300060518815364}

![*FYB* expression validation in different types of breast cancer from different Oncomine databases. (a) *FYB* is upregulated in breast cancer. (b) *FYB* is highly expressed in grade 3 compared with grade 2 breast cancer. (c) Overexpression of *FYB* is observed in breast carcinoma with recurrence at 3 years. (d) *FYB* is overexpressed in breast carcinoma metastasis.](10.1177_0300060518815364-fig5){#fig5-0300060518815364}

###### 

Changes in *HLA-DRA*, *C3AR1*, and *FYB* expression in breast cancer

![](10.1177_0300060518815364-table2)

  Gene                                                  *P* value                               Fold-change                    Dataset (reference)            Number of samples
  -------------------------------- -------------------- --------------------------------------- ------------------------------ ------------------------------ -------------------
  *HLA-DRA*                        Tumor *vs.* normal   0.009                                   1.633                          ^[@bibr28-0300060518815364]^   39
  4.64E-05                         3.101                ^[@bibr29-0300060518815364]^            22                                                            
  0.031                            1.588                ^[@bibr30-0300060518815364]^            89                                                            
  0.001                            1.967                ^[@bibr31-0300060518815364]^            154                                                           
  0.001                            1.971                ^[@bibr32-0300060518815364]^            40                                                            
  1.25E-24                         11.785               ^[@bibr33-0300060518815364]^            59                                                            
  High grade *vs.* low grade       1.18E-04             2.04                                    ^[@bibr34-0300060518815364]^   87                             
  Recurrence vs. no recurrence     0.017                2.287                                   ^[@bibr35-0300060518815364]^   8                              
  *C3AR1*                          Tumor *vs.* normal   5.53E-22                                2.237                          ^[@bibr33-0300060518815364]^   59
  0.007                            2.378                ^[@bibr36-0300060518815364]^            23                                                            
  0.003                            2.295                ^[@bibr36-0300060518815364]^            25                                                            
  0.002                            1.686                ^[@bibr31-0300060518815364]^            158                                                           
  5.61E-04                         1.524                TCGA (No Associated Paper 2011/09/02)   97                                                            
  1.85E-06                         4.758                ^[@bibr29-0300060518815364]^            22                                                            
  High grade *vs.* low grade       0.035                3.373                                   ^[@bibr36-0300060518815364]^   9                              
  8.67E-04                         1.621                ^[@bibr34-0300060518815364]^            87                                                            
  *FYB*                            Tumor *vs.* normal   1.83E-08                                1.911                          ^[@bibr32-0300060518815364]^   38
  0.022                            2.158                ^[@bibr37-0300060518815364]^            38                                                            
  1.17E-12                         2.633                ^[@bibr33-0300060518815364]^            59                                                            
  9.28E-06                         1.557                TCGA (No Associated Paper 2011/09/02)   137                                                           
  1.81E-06                         3.882                ^[@bibr29-0300060518815364]^            22                                                            
  High grade *vs.* low grade       0.009                1.531                                   ^[@bibr36-0300060518815364]^   9                              
  0.038                            1.635                ^[@bibr38-0300060518815364]^            31                                                            
  0.04                             1.58                 ^[@bibr39-0300060518815364]^            43                                                            
  0.041                            2.052                ^[@bibr28-0300060518815364]^            13                                                            
  Recurrence *vs.* no recurrence   0.027                1.523                                   ^[@bibr34-0300060518815364]^   76                             
  Metastasis *vs.* no metastasis   0.03                 1.65                                    ^[@bibr34-0300060518815364]^   76                             

These Oncomine results emphasized the importance of the expression of *HLA-DRA*, *C3AR1*, and *FYB* during breast cancer progression and prognosis.

Discussion {#sec11-0300060518815364}
==========

This study aimed to gain insights into the molecular changes involved in the progression of DCIS to IDC, and to identify novel targets for tumor development or invasion. To address this issue, we download and analyzed two GEO datasets: GSE21422 and GSE3893. Each dataset included gene expression profiles of DCIS and IDC samples.

To identify genes that were conserved in DCIS progression to IDC, we overlapped all DEGs identified from the two datasets to ascertain those that were common to both. A total of 26 genes were common to both datasets, including *MMP11*, *KRT14*, *KRT175,* and *RGS1*, and were previously reported to be correlated with breast tumor invasion or poor prognosis. For example, elevated *MMP11* expression was previously associated with breast cancer invasion and poor clinical outcome,^[@bibr15-0300060518815364]^ while *KRT14* and *KRT17* were reported to be markers of poor prognosis in breast cancer.^[@bibr26-0300060518815364]^ Moreover, *RGS1* inhibition was hypothesized to activate *CXCR4* and further inhibit breast cancer cell survival.^[@bibr27-0300060518815364]^ GO term and KEGG pathway analyses further showed that *FCGR2A*, *HLA-DRA*, *C3AR1*, and *FYB* were involved in most of the top 20 significant GO processes and all KEGG pathways, such as the immune response, suggesting they might play critical roles in DCIS progression. The *FCGR2A* H131R polymorphism is known to be associated with the clinical outcome of patients with breast cancer treated with the sequential adjuvant administration of trastuzumab.^[@bibr28-0300060518815364]^ However, no studies have reported the roles of *HLA-DRA*, *C3AR1*, or *FYB* in breast cancer. In our study, these genes were all upregulated in IDC compared with DCIS.

*HLA-DRA*, an interferon (IFN)-stimulated gene, is highly expressed in MDA MB 435 breast cancer cells within 24 h of IFN-γ stimulation,^[@bibr29-0300060518815364]^ while *C3AR1* expression is increased in basal-like breast malignancies, suggesting it might be associated with immune activation and inflammatory response.^[@bibr30-0300060518815364]^ Moreover, the immune cell-specific adaptor protein FYB, also known as adhesion and degranulation-promoting adapter protein, positively mediates T cell receptor (TCR)-dependent as well as integrin-mediated adhesion, and is involved in pathways downstream of the TCR that may cause T cell activation.^[@bibr31-0300060518815364]^

Our findings showed high expression of *HLA-DRA*, *C3AR1*, and *FYB* in DCIS progression to IDC, but their other characteristics in breast cancer are still unknown. Further support was provided by our Oncomine analysis. Significant levels of *HLA-DRA*, *C3AR1*, and *FYB* overexpression were detected in high-grade relative to low-grade breast carcinoma, and high levels of *HLA-DRA* and *FYB* were correlated with breast carcinoma recurrence, suggesting that *HLA-DRA* and *FYB* expression might be linked to cancer prognosis. This supports an earlier study by Diederichsen et al. which found that increased *HLA-DR* expression was associated with poor prognosis.^[@bibr32-0300060518815364]^ Although no study has yet reported a role for *FYB* expression in cancer prognosis, *FYN* was demonstrated to be a prognostic biomarker for colorectal cancer.^[@bibr33-0300060518815364]^ Additionally, our Oncomine results suggested that elevated levels of *FYB* are related to breast cancer metastasis, further confirming the association between *FYB* and poor prognosis.

Our study has a number of limitations. First, the sample size is limited and the use of larger databases may better explain the molecular characteristics of DCIS progression to IDC, although we nevertheless identified significant DEGs and pathways. Second, while Oncomine analysis successfully validated the expression levels of potential targets in breast cancer, animal work or experimental studies involving human tissues are needed to confirm these findings. In particular, future investigations should determine the roles of *HLA-DRA* and *FYB* in breast cancer prognosis.

In conclusion, our study identified 26 DEGs that may lead to the progression of DCIS to IDC. Among them, *HLA-DRA*, *C3AR1*, and *FYB* appear to be novel key genes involved in the immune response during breast cancer progression. Additionally, *C3AR1* and *FYB* could be associated with breast cancer prognosis. This study identified potential biomarkers for the progression from DCIS to IDC that may be used for breast cancer diagnosis and prevention.
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